
KVUE
Kenvue Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.740
Open
22.630
VWAP
--
Vol
4.22M
Mkt Cap
43.85B
Low
22.430
Amount
--
EV/EBITDA(TTM)
15.76
Total Shares
1.91B
EV
51.53B
EV/OCF(TTM)
26.98
P/S(TTM)
2.87
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
3.87B
+5.67%
0.294
+13.18%
4.02B
+3.13%
0.316
+12.7%
3.90B
-2.61%
0.284
-11.21%
Estimates Revision
The market is revising Upward the revenue expectations for Kenvue Inc. (KVUE) for FY2025, with the revenue forecasts being adjusted by 0.55% over the past three months. During the same period, the stock price has changed by -2.81%.
Revenue Estimates for FY2025
Revise Upward

+0.55%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-1.28%
In Past 3 Month
Stock Price
Go Down

-2.81%
In Past 3 Month
13 Analyst Rating

9.31% Upside
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 24.55 USD with a low forecast of 22.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
8 Hold
0 Sell
Moderate Buy

9.31% Upside
Current: 22.460

Low
22.00
Averages
24.55
High
29.00

9.31% Upside
Current: 22.460

Low
22.00
Averages
24.55
High
29.00
JPMorgan
Overweight -> NULL
downgrade
$27 -> $26
2025-07-25
New
Reason
JPMorgan
Price Target
$27 -> $26
2025-07-25
New
downgrade
Overweight -> NULL
Reason
JPMorgan lowered the firm's price target on Kenvue to $26 from $27 and keeps an Overweight rating on the shares as part of a quarterly earnings preview. The firm expects another challenging quarter for most names in the household and personal care sector.
UBS
Neutral
downgrade
$25 -> $23
2025-07-17
Reason
UBS
Price Target
$25 -> $23
2025-07-17
downgrade
Neutral
Reason
UBS lowered the firm's price target on Kenvue to $23 from $25 and keeps a Neutral rating on the shares.
Citi
Filippo Falorni
Neutral
downgrade
$22
2025-07-15
Reason
Citi
Filippo Falorni
Price Target
$22
2025-07-15
downgrade
Neutral
Reason
Citi analyst Filippo Falorni lowered the firm's price target on Kenvue to $22 from $24.50 and keeps a Neutral rating on the shares. The firm adjusted price targets in the beverages, household and personal care group as part of a Q2 preview. It sees a slightly improved fundamentals across the sector heading into the reports relative to Q1.
BofA
Anna Lizzul
Buy
downgrade
$27 -> $25
2025-07-15
Reason
BofA
Anna Lizzul
Price Target
$27 -> $25
2025-07-15
downgrade
Buy
Reason
BofA analyst Anna Lizzul lowered the firm's price target on Kenvue to $25 from $27 and keeps a Buy rating on the shares. While Kenvue's strategic review and interim CEO announcement suggests a wide range of potential outcomes, BofA is positive on the board's steps to review the portfolio, execution, and path forward, the analyst tells investors in a research note.
Barclays
Lauren Lieberman
Equal Weight
downgrade
$23 -> $22
2025-07-15
Reason
Barclays
Lauren Lieberman
Price Target
$23 -> $22
2025-07-15
downgrade
Equal Weight
Reason
Barclays analyst Lauren Lieberman lowered the firm's price target on Kenvue to $22 from $23 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the staples group as a part of a Q2 preview. Investor expectations "feel subdued" into earnings season, the analyst tells investors in a research note.
Citi
Filippo Falorni
Neutral
maintain
$24.50
2025-06-13
Reason
Citi
Filippo Falorni
Price Target
$24.50
2025-06-13
maintain
Neutral
Reason
Citi analyst Filippo Falorni keeps a Neutral rating on Kenvue with a $24.50 price target after Reuters reported the company is considering a sale of some of its skin health and beauty brands. Many investors Citi has spoken with have questioned the potential for portfolio reshaping activity at Kenvue given the relative underperformance of the skin health and beauty segment, the involvement from three activist investors, and the recent appointment of a new CFO, the analyst tells investors in a research note. As such, the firm believes the Reuters report will not come as a surprise. However, the news could be potentially viewed as a disappointment for investors looking for greater portfolio reshaping actions or other potential strategic options for Kenvue, Citi adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Kenvue Inc (KVUE.N) is 19.67, compared to its 5-year average forward P/E of 18.43. For a more detailed relative valuation and DCF analysis to assess Kenvue Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
18.43
Current PE
19.67
Overvalued PE
20.33
Undervalued PE
16.53
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
12.97
Current EV/EBITDA
13.66
Overvalued EV/EBITDA
13.92
Undervalued EV/EBITDA
12.02
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
2.64
Current PS
2.75
Overvalued PS
2.91
Undervalued PS
2.37
Financials
Annual
Quarterly
FY2025Q1
YoY :
-3.93%
3.74B
Total Revenue
FY2025Q1
YoY :
+1.06%
668.00M
Operating Profit
FY2025Q1
YoY :
+8.78%
322.00M
Net Income after Tax
FY2025Q1
YoY :
+13.33%
0.17
EPS - Diluted
FY2025Q1
YoY :
+85.82%
249.00M
Free Cash Flow
FY2025Q1
YoY :
+1.11%
58.22
Gross Profit Margin - %
FY2025Q1
YoY :
-29.62%
9.48
FCF Margin - %
FY2025Q1
YoY :
+13.29%
8.61
Net Margin - %
FY2025Q1
YoY :
-7.21%
7.21
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
393.8K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
1.1M
Volume
1
3-6
Months
1.2M
Volume
8
6-9
Months
1.9M
Volume
9
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
8
31.2M
Volume
Months
6-9
4
21.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
8.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
16.0K
USD
2
0-12
Months
53.1K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
8.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
393.8K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KVUE News & Events
Events Timeline
2025-07-14 (ET)
2025-07-14
06:48:33
Kenvue sees Q2 adjusted EPS 28c-29c, consensus 28c

2025-07-14
06:47:17
Kenvue names Kirk Perry as Interim CEO, to review strategic alternatives

2025-06-12 (ET)
2025-06-12
19:02:51
Kenvue considering sale of certain brands, Reuters reports


Sign Up For More Events
Sign Up For More Events
News
9.5
07-27CNBCWhy a great company's beat and raise was sold, and what I plan to do with the stock
3.0
07-25NewsfilterKenvue to Announce Second Quarter 2025 Results on August 7, 2025
4.5
07-23NASDAQ.COMAfter Hours Most Active for Jul 23, 2025 : TSLL, INTC, KVUE, VERV, GOOGL, GOOG, NVDA, PATH, CMG, RKT, KMI, QS
Sign Up For More News
People Also Watch

XEL
Xcel Energy Inc
71.550
USD
-1.53%

VALE
Vale SA
9.800
USD
-2.00%

CTSH
Cognizant Technology Solutions Corp
75.640
USD
-1.34%

ARGX
argenx SE
596.930
USD
+0.83%

NET
Cloudflare Inc
200.030
USD
+0.81%

CCI
Crown Castle Inc
109.350
USD
-1.91%

GEHC
GE Healthcare Technologies Inc
78.250
USD
+0.82%

CPNG
Coupang Inc
30.060
USD
-0.63%

IT
Gartner Inc
354.160
USD
-0.70%

VRSK
Verisk Analytics Inc
295.580
USD
-0.80%
FAQ

What is Kenvue Inc (KVUE) stock price today?
The current price of KVUE is 22.46 USD — it has decreased -1.66 % in the last trading day.

What is Kenvue Inc (KVUE)'s business?

What is the price predicton of KVUE Stock?

What is Kenvue Inc (KVUE)'s revenue for the last quarter?

What is Kenvue Inc (KVUE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Kenvue Inc (KVUE)'s fundamentals?

How many employees does Kenvue Inc (KVUE). have?
